HRD1 inhibits fatty acid oxidation and tumorigenesis by ubiquitinating CPT2 in triple‐negative breast cancer-Reference-Cited by-同舟云学术

HRD1 inhibits fatty acid oxidation and tumorigenesis by ubiquitinating CPT2 in triple‐negative breast cancer

Published:2020-12-16 Issue:2 Volume:15 Page:642-656
ISSN:1574-7891
Container-title:Molecular Oncology
language:en
Short-container-title:Mol Oncol

Author:

Guo Xin¹²^ORCID,Wang Aman¹³,Wang Wen²⁴,Wang Ya¹,Chen Huan²,Liu Xiaolong²,Xia Tian²,Zhang Aijia¹,Chen Di²,Qi Huan²,Ling Ting²,Piao Hai‐long²⁵^ORCID,Wang Hong‐jiang¹^ORCID

Affiliation:

1. First Affiliated Hospital of Dalian Medical University Dalian Medical University China

2. CAS Key Laboratory of Separation Science for Analytical Chemistry Dalian Institute of Chemical Physics Chinese Academy of Sciences Dalian China

3. Liaoning Key Laboratory of Molecular Targeted Drugs in Hepatobiliary and Pancreatic Cancer Dalian China

4. University of Chinese Academy of Sciences Beijing China

5. Department of Biochemistry & Molecular Biology School of Life Sciences China Medical University Shenyang China

Funder

National Natural Science Foundation of China

Doctoral Start-up Foundation of Liaoning Province

Dalian Institute of Chemical Physics

Publisher

Wiley

Subject

Cancer Research,Genetics,Molecular Medicine,General Medicine,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/1878-0261.12856

Reference34 articles.

1. Molecular Classification and Molecular Forecasting of Breast Cancer: Ready for Clinical Application?

2. Triple-negative breast cancer—current status and future directions

3. The Emerging Hallmarks of Cancer Metabolism

4. Metabolic Reprogramming in Triple-Negative Breast Cancer

5. Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cholesterol suppresses AMFR-mediated PDL1 ubiquitination and degradation in HCC;Molecular and Cellular Biochemistry;2024-09-04

2. Mitochondrial inhibitors: a new horizon in breast cancer therapy;Frontiers in Pharmacology;2024-07-04

3. ACSL3 regulates breast cancer progression via lipid metabolism reprogramming and the YES1/YAP axis;Cancer Biology & Medicine;2024-07-01

4. SYVN1 modulates papillary thyroid carcinoma progression by destabilizing HMGB1;Cell Division;2024-04-28

5. SYVN1-mediated ubiquitylation directs localization of MCT4 in the plasma membrane to promote the progression of lung adenocarcinoma;Cell Death & Disease;2023-10-10